ストックスクリーナーアプリを入手
68.10
2.79%
1.85
前日終値:
$66.25
開ける：
$67.28
24時間の取引高:
595.32K
Relative Volume:
0.78
時価総額：
$3.42B
収益：
$76.81M
当期純損益:
$-162.42M
株価収益率:
-22.78
EPS:
-2.99
ネットキャッシュフロー:
$-122.49M
1週間 パフォーマンス:
+9.73%
1か月 パフォーマンス:
+28.98%
6か月 パフォーマンス:
-19.46%
1年 パフォーマンス:
+32.65%
1日の値動き範囲:
$66.44
$68.84
1週間の範囲:
$61.00
$68.84
52週間の値動き範囲:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
ACLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
68.10 | 3.42B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-03-07 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-04 | 繰り返されました | Needham | Buy |
| 2023-12-19 | 開始されました | Scotiabank | Sector Outperform |
| 2023-10-30 | 開始されました | TD Cowen | Outperform |
| 2023-10-17 | 開始されました | UBS | Buy |
| 2023-05-18 | 開始されました | Truist | Buy |
| 2023-04-14 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-14 | 開始されました | Stifel | Buy |
| 2023-02-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-13 | 再開されました | BofA Securities | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-27 | 開始されました | Needham | Buy |
| 2022-07-20 | 開始されました | Canaccord Genuity | Buy |
| 2022-03-01 | 開始されました | BofA Securities | Buy |
| 2022-03-01 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Arcellx Inc (ACLX) 最新ニュース
FY2026 EPS Estimates for Arcellx Lifted by Leerink Partnrs - Defense World
Squarepoint Ops LLC Sells 4,670 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx FY2029 EPS Forecast Raised by Leerink Partnrs - Defense World
Top NASDAQ Stocks Arcellx’s Role by Kalkine - Kalkine Media
Two Sigma Advisers LP Acquires 1,100 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Millennium Management LLC Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Ameriprise Financial Inc. Sells 945 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
How to Take Advantage of moves in (ACLX) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 9,110 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc Holds Annual Stockholders Meeting - TipRanks
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Thinking Of Buying Arcellx Inc (NASDAQ: ACLX) Stock? Here’s What You Need To Know - Stocksregister
Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Bluefield Daily Telegraph
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga
Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Insider Monkey
BNP Paribas Financial Markets Makes New $1.53 Million Investment in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail
Mercer Global Advisors Inc. ADV Takes $278,000 Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Arcellx - Defense World
Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com
Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy - TipRanks
Arcellx Announces Positive Phase 2 Study Results - TipRanks
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - BioSpace
Arcellx Reports Positive Data From Phase 2 IMMagine-1 Study - Nasdaq
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel - TipRanks
Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma - marketscreener.com
Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating - TipRanks
Here’s Why Arcellx (ACLX) Declined in Q1 - Insider Monkey
Arcellx, Inc. (NASDAQ:ACLX) Receives $109.31 Average Target Price from Brokerages - Defense World
Scotiabank Has Lowered Expectations for Arcellx (NASDAQ:ACLX) Stock Price - Defense World
Piper Sandler Remains a Buy on Arcellx Inc (ACLX) - The Globe and Mail
Arcellx Inc (ACLX) Receives a Buy from Scotiabank - The Globe and Mail
Arcellx First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Needham Sticks to Their Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Arcellx (ACLX) Maintains Rating as Price Target is Lowered by Sc - GuruFocus
Arcellx price target lowered to $93 from $133 at Scotiabank - TipRanks
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Promising Potential of Arcellx Inc’s Anito-cel Therapy: A Buy Rating Backed by Positive Study Data and Strategic Trial Enhancements - TipRanks
Arcellx (ACLX): Scotiabank Adjusts Price Target Amid Regulatory Concerns | ACLX Stock News - GuruFocus
Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target - TipRanks
Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating - TipRanks
ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings - Nasdaq
Earnings Flash (ACLX) ARCELLX INC. Reports Q1 Revenue $8.1M, vs. FactSet Est of $19.5M - marketscreener.com
Arcellx Inc (ACLX) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):